Resigratinib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, small molecule, irreversible pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, resigratinib covalently binds to and inhibits all four FGFR subtypes, FGFR1, FGFR2, FGFR3 and FGFR4, including wild-type FGFR family proteins, and FGFR2 and FGFR3 gatekeeper, molecular brake, and activation loop mutations. This prevents FGFR-mediated signaling, and inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis.

**Synonyms:** - KIN 3248 - KIN-3248 - KIN3248 - Pan FGFR Inhibitor KIN-3248 - Pan-FGFR Inhibitor KIN-3248 - Pan-fibroblast Growth Factor Receptor Inhibitor KIN-3248 - RESIGRATINIB